NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
December 21 2023 - 8:30AM
NightHawk Biosciences (NYSE American:
NHWK) (“NightHawk” or the “Company”), an integrated
contract development and manufacturing organization (CDMO), today
announced its Scorpius BioManufacturing subsidiary (“Scorpius”)
completed a demonstration run in the Company’s process development
lab for a microbial vaccine program developed by a top-tier
research university that is NIH and DTRA (Defense Threat Reduction
Agency) funded.
Jeff Wolf, CEO of NightHawk, commented, “This
first phase of a multi-million-dollar project was particularly
noteworthy, as we achieved a successful demonstration run following
a prior failed attempt by a competitor CDMO. The complexity of the
project led this top-tier university to choose Scorpius, drawn by
our more engaged management approach and accelerated development
timeline. The successful completion of this demonstration run
showcases our team's dedication and expertise, and represents an
important step in advancing our relationship with this nationally
renowned university. The next phase of this project will include
scaling up to cGMP manufacturing to support a phase 1 infectious
disease trial. Our CDMO services continue to attract considerable
interest, thanks to our extraordinary team, state-of-the-art
facilities, and the industry-wide scarcity of capacity for large
molecule manufacturing.”
NightHawk Biosciences,
Inc.NightHawk Biosciences, through its Scorpius
BioManufacturing subsidiary, is an integrated contract development
and manufacturing organization (CDMO) focused on rapidly advancing
biologic and cell therapy programs to the clinic and beyond.
Scorpius offers a broad array analytical testing, process
development, and manufacturing services to pharmaceutical and
biotech companies at its state-of-the art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit: www.nighthawkbio.com or
www.scorpiusbiologics.com, and also follow us on Twitter.
Forward Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as recognizing revenue
from the agreement during 2024, expanding our scope of work and
revenue potential of this agreement and the CDMO activities holding
the potential to generate meaningful revenue and cash flow
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to generate future revenue from manufacturing
contracts booked in 2023 the Company’s ability to continue to grow
revenue, leverage fixed costs and achieve long-term profitability;
the Company’s ability to create substantial shareholder value as a
pure-play CDMO in an underserved marketplace; the Company’s
financing needs, its cash balance being sufficient to sustain
operations and its ability to raise capital when needed, the
Company’s ability to successfully operate as a CDMO, he continued
maintenance and growth of the Company’s and its subsidiaries’
patent estates the ability to obtain regulatory approval or to
comply with ongoing regulatory requirements, regulatory limitations
relating to the Company’s ability to successfully promote its
services and compete as a pure- play CDMO, and other factors
described in the Company’s annual report on Form 10-K for the year
ended December 31, 2022, subsequent quarterly reports on Form 10-Qs
and any other filings the Company makes with the SEC. The
information in this presentation is provided only as of the date
presented, and the Company undertakes no obligation to update any
forward-looking statements contained in this presentation on
account of new information, future events, or otherwise, except as
required by law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Apr 2023 to Apr 2024